Sigma-Tau Research, Inc. is a national leader in the development of compounds
used in a variety of clinical indications. Ongoing and planned research
includes applications for central and peripheral nervous system, oncology and cardiovascular
disease.
Sigma-Tau Research is developing a series of compounds, in a variety of
clinical indications, for the USA market.
- Propionyl-L-carnitine (ST 261)
This compound is in development for Intermittent Claudication and End Stage Renal Disease.
Future development areas will focus on the cardiovascular system.
- Acetyl-L-carnitine (ST 200)
This compound has been developed to treat both Alzheimer's disease and
peripheral diabetic neuropathy, where it has completed phase III trials.
Acetyl-L-carnitine is also in development for Cancer induced fatigue and cancer induced neuropathy. Future
areas of development will continue to revolve around cognition and peripheral neuropathy of different
origins.
Click here to learn about gratifying career opportunities at Sigma-Tau Research, Inc.
Contact Sigma-Tau Research, Inc. for business development
inquires for compounds in clinical development.
|
